Charles Zhu

“Maybe one from me regarding frontline non-small cell lung cancer. So great to see either current or ongoing plans with various mutant-selective inhibitors in combination with standard of care.”

“And thank you for putting out your data and for hosting this event. Two questions from me. One, could you perhaps elaborate a bit more on the specific prior treatment history for your patients here?”

“No technical difficulties this afternoon. Thank you very much for taking our questions, and congrats on all the progress. Two quick ones from me, if you don't mind.”

“I got a call kind of at the opposite end of the spectrum. One, how many patients do you think you can accommodate on your expanded access program for the RACs on RACs?”

“Recognizing that these data are from about four and a half months ago and not that many patients were valuable at 60-milligram Cabo combinations. Could you talk about the decision to expand at some of these 60-milligram Cabo combinations, maybe what you've seen?”